Panel Discussion/ Q&A: Plants as new sources of medicinals: Production of protein pharmaceuticals in food and non-food plants

dc.contributor.author	Miller, Henry
dc.contributor.author	Nelson, Mark
dc.date.accessioned	2017-06-07T17:49:25Z
dc.date.available	2017-06-07T17:49:25Z
dc.date.issued	2005
dc.description.abstract	Regulation of transgenic organisms should not be based on the process used to produce them but rather than on the host and the added trait. Highly activist and more moderate public-interest organizations and the regulatory system and associated costs have debilitated public-sector agricultural biotechnology. There is concern over the possibility of adulteration of food if PMPs are produced in crops such as corn, soy and canola. The Grocery Manufacturers of America has asked for a safety evaluation of the implications if PMP-producing food crops are commingled in the food supply; reasonable standards are needed.
dc.identifier.uri	https://hdl.handle.net/1813/51002
dc.language.iso	en_US
dc.publisher	NABC
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Agricultural biotechnology
dc.subject	environment, human health
dc.subject	GMO, genetic engineering, pharming
dc.subject	plant based vaccines
dc.subject	medicinals
dc.subject	regulation
dc.subject	liability, patents
dc.subject	stewardship
dc.title	Panel Discussion/ Q&A: Plants as new sources of medicinals: Production of protein pharmaceuticals in food and non-food plants
dc.type	book chapter

Files

Now showing 1 - 1 of 1